Oncology ESMO 2025: ITM's Dr Andrew Cavey on next-gen RPTs At ESMO, pharmaphorum spoke with radiopharmaceutical biotech Isotope Technologies Munich SE (ITM) CEO Dr Andrew Cavey.
Oncology ESMO25: Patient-centric oncological futures with Boehringer ... On new oncology data from Boehringer Ingelheim, with Lykke Hinsch Gylvin, chief medical officer, and Itziar Canamasas, head of oncology, at ESMO 2025.
Oncology ESMO 2025 commences: ADCs, AI, and Asia ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.
Oncology Pre-ESMO insights: Corcept on platinum-resistant ovarian can... pharmaphorum speaks with Corcept Therapeutics about its presentation of data in platinum-resistant ovarian cancer at both ASCO and ahead of ESMO 2025.
Oncology Advancing radiopharmaceutical development: Preclinical preci... Radiopharmaceutical development must move beyond fixed paradigms toward patient-specific, data-driven optimisation.
Oncology News and advice from an investor-CEO, with Milenko Cicmil pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.
News NHS staff 'feel unprepared for digital transformation' A survey of NHS workers has found that almost two-thirds feel they are unprepared for the digital transformation objectives of the 10-Year Plan.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
